Sorrento Therapeutics (NASDAQ:SRNE)‘s stock had its “buy” rating reaffirmed by Oppenheimer in a note issued to investors on Friday. They presently have a $9.00 price objective on the biopharmaceutical company’s stock. Oppenheimer’s price objective indicates a potential upside of 40.63% from the company’s current price.
Several other analysts have also commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price (up from $20.00) on shares of Sorrento Therapeutics in a report on Tuesday. BidaskClub raised Sorrento Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, January 6th. Finally, ValuEngine raised Sorrento Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 3rd. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. Sorrento Therapeutics has a consensus rating of “Buy” and a consensus target price of $13.67.
Sorrento Therapeutics (SRNE) traded up $0.35 during trading on Friday, reaching $6.40. The company had a trading volume of 2,774,797 shares, compared to its average volume of 2,646,261. The firm has a market capitalization of $507.66, a price-to-earnings ratio of -15.24 and a beta of 1.04. Sorrento Therapeutics has a 12-month low of $1.50 and a 12-month high of $6.47. The company has a debt-to-equity ratio of 0.18, a quick ratio of 0.54 and a current ratio of 0.54.
Sorrento Therapeutics Company Profile
Sorrento Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases.
Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.